The biopharmaceutical company Omnix Medical, known for creating advanced anti-infectives to combat serious infections, has reported today that their upcoming Phase II trial for their innovative anti-infective, OMN6, has received approval from the FDA.

The OCEANIC-AF phase III trial comparing asundexian and apixaban in stroke-risk atrial fibrillation patients will end early. This is based on the Independent Data Monitoring Committee's recommendation, as asundexian showed lower efficacy than the control. Bayer will analyze the data further and share the results later.

Vigil Neuroscience has revealed encouraging initial results from the Phase 2 IGNITE clinical trial. This trial aims to test the potential of Iluzanebart (VGL101) in treating ALSP.

AskBio reveals the enrollment of their initial patient into the Phase 1 trial for AB-1005 (AAV2-GDNF), their gene therapy solution to Multiple System Atrophy-Parkinsonian Type (MSA-P).

Medicenna reports promising survival gains from the Phase 2b trial of Bizaxofusp for relapsed Glioblastoma, revealed at the 28th yearly NeuroOncology Society gathering.

EBGLYSS® (lebrikizumab), developed by Almirall, has been given the green light by the European Commission for the treatment of moderate-to-severe atopic dermatitis.

US approval granted for combination of Truqap (capivasertib) and Faslodex for treating advanced HR-positive breast cancer patients.

Polaris Group commences phased submission of a BLA for ADI-PEG 20 to the U.S. FDA to manage Malignant Pleural Mesothelioma.

Astellas and Pfizer's XTANDI® gets FDA approval for update, following fast-tracked review and EMBARK study results.

Q32 Bio, a biotech company in clinical phase, is regaining full rights for bempikibart (formerly ADX-914) from Amgen to focus on developing immune-balancing biologic therapies.

argenx reveals green light from European Commission for the subcutaneous usage of VYVGART® (efgartigimod alfa) in treating Generalized Myasthenia Gravis.

The first patient was treated with ALE.C04 in a Phase 1/2 study by Alentis Therapeutics, aimed at treating Head and Neck Squamous Cell Carcinoma (HNSCC).